Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)‘s stock had its “outperform” rating reissued by equities research analysts at Oppenheimer Holdings Inc. in a report issued on Wednesday. They currently have a $10.00 price objective on the stock. Oppenheimer Holdings Inc.’s price objective suggests a potential upside of 484.80% from the company’s previous close.
Separately, Roth Capital reiterated a “buy” rating and issued a $6.00 price target on shares of Pieris Pharmaceuticals in a report on Wednesday.
Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.71 on Wednesday. Pieris Pharmaceuticals has a 52 week low of $1.26 and a 52 week high of $3.08. The stock’s market capitalization is $73.63 million. The firm has a 50-day moving average of $1.63 and a 200 day moving average of $1.79.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative return on equity of 52.21% and a negative net margin of 346.01%. The company had revenue of $1.07 million for the quarter. On average, analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current year.
Several large investors have recently modified their holdings of PIRS. Sabby Management LLC increased its stake in shares of Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock worth $333,000 after buying an additional 99,792 shares during the period. BVF Inc. IL purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $389,000. Lombard Odier Asset Management USA Corp increased its stake in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares during the period. Frontier Wealth Management LLC purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $137,000. Finally, BlackRock Fund Advisors purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $113,000. Institutional investors and hedge funds own 45.79% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.